CN103641791A - Cyclopeptide compound clavatustide B, and preparation method and application thereof - Google Patents
Cyclopeptide compound clavatustide B, and preparation method and application thereof Download PDFInfo
- Publication number
- CN103641791A CN103641791A CN201310574939.4A CN201310574939A CN103641791A CN 103641791 A CN103641791 A CN 103641791A CN 201310574939 A CN201310574939 A CN 201310574939A CN 103641791 A CN103641791 A CN 103641791A
- Authority
- CN
- China
- Prior art keywords
- clavatustide
- preparation
- cyclic peptide
- peptide compounds
- fermentation culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a cyclopeptide compound clavatustide B, and a preparation method and application thereof. Clavatustide B has the structural formula shown as the formula (I). The preparation method of clavatustide B comprises: inoculating activated aspergillus clavatus with a preservation number of CCTCC No. M2013421 to a fermentation culture solution to perform fermentation culturing; after fermentation is finished, performing separation to obtain mycelium and a broth; and performing chromatographic separation and purifying processing on mycelium extract or broth extract to prepare the cyclopeptide compound. The application means the application of the cyclopeptide compound to prepare anti-tumor medicaments or anti-tumor health-care foodstuff. The cyclopeptide compound provided by the invention has relatively good in-vitro anti-tumor activity, has the IC50 value to HepG2 cell of 15 mu g/mL, and has good develop prospect; and the preparation method is simple in operation and is suitable for large-scale production.
Description
Technical field
The invention belongs to thalassiomycetes active substance field, be specifically related to a kind of cyclic peptide compounds clavatustide B and its preparation method and application.
Background technology
Marine microorganism is owing to living under pressure environment, and its secondary metabolic product often has the biological activity that land fungus twice meta-bolites does not possess, and becomes in recent years the focus of drug development.Marine microorganism not only struggle for existence pressure is very large; pH scope, temperature, pressure, dissolved oxygen, light, nutrition and the salinity etc. of its residing ocean environment are all different from terrestrial environment; this is the multifarious basis of marine microorganism secondary metabolic product (Debbab, A.; Aly, A.H.; Lin, W.H.; Proksch, P.Microb.Biotech.2010,3,544 – 563; Saleema, M.; Ali, M.S.; Hussain, S.; Jabbar, A.; Ashraf, M.; Lee, Y.S.Nat.Prod.Rep.2007,24,1142 – 1152; Wu, B.; Wu, X.; Sun, M.; Li, M.Mar.Drugs2013,11,2713-2721.).
Thalassiomycetes is as the important component part of marine microorganism, and the aspects such as, oil degradation synthetic at medicine, environment remediation have vital role.Thalassiomycetes had both had the typical protein modified performance of eukaryote, had again upper easy, the advantage fast of microorganism operation, as new eukaryotic expression system, had huge potential and wide application prospect.Along with going deep into that marine microorganism is studied, found increasing anti-tumor active substance from thalassiomycetes in recent years, thalassiomycetes becomes the another study hotspot after marine actinomycete.
(Xu is red for natural pond Tian Dun etc., Gu Qianqun, the refined .2001 of Cui Cheng. the progress of studies of antitumor metabolites from marine microorganisms [J]. Chinese Sea medicine .6:44-49.) penicillium being separated to from Enteromorpha marine alga Enteromorpha intestinalis body surface has been carried out to a series of research.This bacterial strain is placed in to the sea water medium containing 2% glucose, 1% peptone and 0.5% yeast extract paste; cultivate 3 weeks for 27 ℃; first separation obtains 2 cell toxicant meta-bolites Communesins A and B, and in the two structure, only acyl side-chain is deposited difference, but in activity, has differed nearly 10 times.
(Xu is red for natural pond Tian Dun etc., Gu Qianqun, the refined .2001 of Cui Cheng. the progress of studies of antitumor metabolites from marine microorganisms [J]. Chinese Sea medicine .6:44-49.) also from be located away from the GI aspergillus Aspergillus of ocean fish Pseudolabrus japonicus fummigatus mycelium, be separated to a series of cytotoxic compound Fumiquinazolines A～G, P385 cell is had to medium cytotoxicity.The people such as Fenieal obtain four sesquiterpene oil of mirbane ester cpds from the Aspergillus versicolor of Caribbean Sea green alga Penicillus capitatus body surface separation, 9a wherein, the IC of 14-dihydroxyl-6 p-nitrobenzoic acid cinnamic ester to 60 of NCI mankind's tumor cell groups
50mean value be 1.1mg/L, but to the selective toxicity of 5 kinds of kidney cancer cells (786-0, ACHN, CAK-1, TK-10, VO-31), average IC
50for 0.51mg/L.
Ocean hydrothermal solution mouth is most active environment (Thornburg, C.C. on the earth; Zabriskie, T.M.; McPhail, K.L.J.Nat.Prod.2010,73,489 – 499.), hydrothermal solution mouth crab (Xenograpsus testudinatus) just lives in extremely, toxicity, be covered with near the hydrothermal solution mouth of sulfide.This hydrothermal solution mouth crab is found (eng, M.-S. in Kueishan Island, Taiwan; Ng, N.K.; Ng, P.K.L.Nature2004,432,969.), up to now, nobody studies the meta-bolites of the epiphytic fungi of this hydrothermal solution mouth crab.
Summary of the invention
The invention provides a kind of cyclic peptide compounds clavatustide B, this compound extracts and obtains from hydrothermal solution mouth crab Xenograpsus testudinatus grows nonparasitically upon another plant excellent aspergillus Aspergillus clavatus C2WU fermenting culture, has stronger anti-tumor activity.
A cyclic peptide compounds clavatustide B, structural formula is as shown in formula I:
The present invention also provides the preparation method of described cyclic peptide compounds clavatustide B, comprises the following steps:
(1) activated excellent aspergillus (Aspergillus clavatus) CCTCC No.M 2013421 is inoculated in fermentation culture, in 20-30 ℃ of fermentation culture 10-60 days;
Described excellent aspergillus (Aspergillus clavatus) CCTCC No.M 2013421 separation from hydrothermal solution mouth crab (Xenograpsus testudinatus) obtains, and is the epiphytic fungi of hydrothermal solution mouth crab (Xenograpsus testudinatus); This bacterial strain is preserved on September 14th, 2013 the Chinese Typical Representative culture collection center (China Center for Type Culture Collection, CCTCC) that is positioned at Luo Jia Shan, Wuhan City Wuhan University, and preserving number is: CCTCC No.M 2013421.
Due to excellent aspergillus (Aspergillus clavatus), C2WU is fungi, adopts conventional PDA liquid nutrient medium or malt extract medium to can be used for fermentation.But in order to simulate better the primary ocean environment of excellent aspergillus C2WU, enough nutritive ingredients are provided to microorganism growth metabolism, as preferably, in step (1), in 1L, the consisting of of described fermentation culture: starch 1-5g, wheat bran 10-20g, yeast extract paste 3-15g, KH
2pO
40.1-0.8g, MgSO
47H
2o 0.1-0.8g, surplus is seawater.
Or, in 1L, the consisting of of described fermentation culture: potato 200-600g, peptone 2-10g, yeast extract paste 1-5g, glucose 5-20g, surplus is seawater; Nutrient solution initial pH value is 6.0～7.0.
Or, in 1L, the consisting of of described fermentation culture: sucrose 20-40g, yeast extract 8-12g, malt extract 18-22g, MgSO
47H
2o 0.3-0.5g, KH
2pO
40.3-0.5g, surplus is seawater.
As further preferably, in step (1), in 1L, the consisting of of described fermentation culture: starch 3g, wheat bran 14g, yeast extract paste 6g, KH
2pO
40.5g, MgSO
47H
2o 0.4g, surplus is seawater.
Or, in 1L, the consisting of of described fermentation culture: potato 400g, peptone 6g, yeast extract paste 2g, glucose 10g, surplus is seawater; Nutrient solution initial pH value is 6.5.
Or, in 1L, the consisting of of described fermentation culture: sucrose 20.0g, yeast extract 10.0g, malt extract 20g, MgSO
47H
2o 0.4g, KH
2pO
40.4g, surplus is seawater.
It is 10 that described excellent aspergillus C2WU is made to concentration
7～10
9the spore suspension of cfu/mL, is inoculated in fermentation culture with 8～12% inoculum sizes, carries out fermentation culture.Preferably, the temperature of described fermentation culture is 20-30 ℃, and the time is 10-60 days.More preferably, the temperature of described fermentation culture is 22-26 ℃, and the time is 15-25 days.Most preferably, the temperature of described fermentation culture is 24 ℃, and the time is 20 days.Under this fermentation culture conditions, the output of described cyclic peptide compounds clavatustide B is the highest.
Fermentation culture adopts static cultivation mode, also can carry out shake-flask culture, while adopting shake-flask culture, and optionally corresponding shortening of fermentation time.
(2), after having fermented, separation obtains mycelium and fermented liquid;
In the present invention, the mycelium obtaining from fermenting with in fermented liquid, all can extract, separatedly obtain described cyclic peptide compounds clavatustide A.Wherein, while utilizing mycelium to obtain clavatustide A, mycelium is placed in to organic solvent lixiviate, obtain vat liquor, again with distilled water to vat liquor suspendible, obtain aqueous suspension, then with ethyl acetate or chloroform, aqueous suspension is extracted, be extracted liquid A, extraction liquid A obtains mycelium extract after concentrated;
During lixiviate, the weightmeasurement ratio of mycelium and organic solvent is preferably 50～500g:1L, more preferably 100g:1L.Described organic solvent can be selected one or both in methyl alcohol, ethanol, ethyl acetate and acetone, is preferably methyl alcohol or acetone, and under methyl alcohol or acetone soak, mycelia physical efficiency, by abundant broken wall, makes the effective stripping of intracellular organic matter.
While utilizing fermented liquid to obtain clavatustide B, with ethyl acetate or chloroform, fermented liquid is extracted, be extracted liquid B, extraction liquid B obtains fermentation broth extract after concentrated.
(3) mycelium extract or fermentation broth extract are carried out to chromatographic separation, purification process, make described cyclic peptide compounds clavatustide B;
As preferably, described chromatographic separation is purification on normal-phase silica gel column chromatography for separation, and eluent is petrol ether/ethyl acetate mixed solution.During chromatographic separation, the petrol ether/ethyl acetate mixed solution that the volume ratio of take is successively 9:1,5:1,1:1,1:3,1:9 carries out wash-out, and collected volume is than the cut eluting for the petrol ether/ethyl acetate mixed solution of 5:1.
In the target fraction obtaining through purification on normal-phase silica gel column chromatography for separation, described cyclic peptide compounds also contains a small amount of impurity, obtains the target compound that purity is higher if want, also needs this target fraction to be further purified processing.The method of described purification process is optional: recrystallization, reversed-phase silica gel column chromatography separation or high performance liquid chromatography are separated.
Wherein, while adopting reversed-phase silica gel column chromatography separation to carry out purifying, preferred eluent is methanol/water mixed solution; More preferably, described methanol/water mixed solution by volume 9:1,5:1,1:1,1:3,1:9 carries out gradient elution, and collected volume is than the cut eluting for the methanol/water mixed solution of 1:1.
Thus, the present invention also provides the application of described cyclic peptide compounds clavatustide B in preparing antitumor drug or tumor prevention protective foods.This antitumor drug be take cyclic peptide compounds of the present invention as main active ingredient, adds acceptable auxiliary material in pharmaceutics and makes, and can make preparation according to the formulation preparation method of recording in pharmaceutics.Described preparation can be for injection liquid, drip liquid, powder injection, granule, tablet, electuary, powder, oral liquid, sugar coated tablet, film coated tablet, enteric coated tablet, suck agent, granule, pill, paste, sublimed preparation, sprays, pill, disintegrating agent, orally disintegrating tablet, micropill etc.This tumor prevention protective foods be take cyclic peptide compounds of the present invention as main active ingredient, adds acceptable protective foods auxiliary material and makes.
As preferably, described antitumor drug is medicines resistant to liver cancer, and described tumor prevention protective foods is prevention of hcc protective foods.Utilize this cyclic peptide compounds to carry out antitumor activity in vitro, show that this cyclic peptide compounds has good anti tumor activity in vitro, its IC to HepG2 cell
50value is 15 μ g/mL.
Compared with prior art, beneficial effect of the present invention is:
The present invention utilizes polarity difference extraction from the fermenting culture of crab epiphytic fungi rod aspergillus C2WU, the separation of cyclic peptide to obtain a kind of cyclic peptide compounds clavatustide B with novel structure, the method is easy and simple to handle, extraction yield is high, product purity is high, is applicable to large-scale production; And this compound has good anti tumor activity in vitro, its IC to HepG2 cell
50value is 15 μ g/mL, can be used for preparing medicines resistant to liver cancer or prevention of hcc protective foods, has good DEVELOPMENT PROSPECT.
Accompanying drawing explanation
Fig. 1 is cyclic peptide compounds clavatustide B's of the present invention
1h
1h COSY, the HMBC collection of illustrative plates of being correlated with;
Fig. 2 is the circular dichroism spectrogram of cyclic peptide compounds clavatustide B of the present invention; Wherein, upper figure is CD spectrogram, and the Y-axis mdeg of CD spectrogram represents milli degree, and X-axis is wavelength nm; Figure below is ultraviolet spectrogram, and the Y-axis of ultraviolet spectrogram represents absorbancy, and X-axis is wavelength nm;
Fig. 3 is cyclic peptide compounds clavatustide B's of the present invention
1h NMR nuclear magnetic spectrum;
Fig. 4 is cyclic peptide compounds clavatustide B's of the present invention
13c NMR nuclear magnetic spectrum;
Fig. 5 is the DEPT NMR nuclear magnetic spectrum of cyclic peptide compounds clavatustide B of the present invention;
Fig. 6 is the COSY NMR nuclear magnetic spectrum of cyclic peptide compounds clavatustide B of the present invention;
Fig. 7 is the HSQC NMR nuclear magnetic spectrum of cyclic peptide compounds clavatustide B of the present invention;
Fig. 8 is the HMBC NMR nuclear magnetic spectrum of cyclic peptide compounds clavatustide B of the present invention;
Fig. 9 is the infrared spectrogram of cyclic peptide compounds clavatustide B of the present invention.
Embodiment
Embodiment 1
(1) separated fungi from hydrothermal solution mouth crab
Hydrothermal solution mouth crab Xenograpsus testudinatus receives in the Ye Ying of oceanography institute of Zhejiang University and teaches.First use aseptic seawater flushing hydrothermal solution mouth crab 3 times, remove non-attached microbial; By shell and the separate tissue of hydrothermal solution mouth crab, under aseptic condition, scrape lower housing powder again; Then in shell powder, add seawater to make serial gradient dilution (1:5,1:25,1:125,1:625), with vortex vibrator vibration 10min, obtain suspension; Centrifugal this suspension 20min under 5000r/min,, supernatant liquor inclines; A small amount of aseptic seawater resuspension for throw out, gets the resuspended liquid of 0.1mL and coats GYP substratum (1.0g glucose, 0.1g yeast extract, 0.5g peptone, 15g agar, 1L seawater) flat board; At 20 ℃ of room temperatures, cultivate after 10d, picking list bacterium colony moves at 4 ℃, inclined-plane and saves backup after line purifying.
(2) differentiate separated fungi
When separated fungi grows on PDA substratum, white mycelium, have every, colony edge has the thin layer aerial hyphae of wide 2-6mm, aerial hyphae is felt shape, is close to matrix growth; The spore head growing from the raw mycelia of base is abundant, and the top capsule of spore head is bar-shaped, and surface is robin's egg blue, is white during children; All there is transparence secretory product on the top of top capsule and aerial hyphae, and bacterium colony reverse side is tawny, has the radial texture of concentric(al) circles, and texture place color is darker.
Extract strain gene group DNA simultaneously, its ITS gene carry out sequencing of increasing, the base sequence of ITS gene is as shown in SEQ ID No.1.
According to the morphological specificity of bacterial strain and ITS the sequencing results, identify that this bacterial strain is excellent aspergillus Aspergillus clavatus, called after rod aspergillus C2WU.
(3) fermentation culture
Activated excellent aspergillus C2WU is made to concentration 10
8cfu/mL spore suspension, is inoculated in fermentation culture with 10% inoculum size, in 24 ℃ of static fermentations, cultivates 20 days.
Wherein, nutrient solution formula is: potato 400g, peptone 6g, yeast extract paste 2g, glucose 10g, seawater 1000mL; The initial pH value of fermentation culture is 6.5.
(4) cyclic peptide compounds preparation
After rod aspergillus C2WU fermentation culture, get 5L fermentation culture, centrifuging and taking precipitation obtains mycelium; Methyl alcohol lixiviate 1 week for mycelium, obtains vat liquor; Vat liquor with 1L distilled water suspendible, obtains aqueous suspension after concentrated; 6L ethyl acetate extraction for aqueous suspension, obtains acetic acid ethyl acetate extract, and acetic acid ethyl acetate extract obtains medicinal extract 10g after concentrated; By silica gel for medicinal extract, (100 orders, 100g) mix sample, carry out purification on normal-phase silica gel column chromatography for separation (200-300 order, 100g; Silicagel column size L50mm,
12mm), the petrol ether/ethyl acetate mixed solution with volume ratio 9:1,5:1,1:1,1:3,1:9 carries out gradient elution successively, each 300mL; TLC detects cut, and the cut of collecting wash-out ratio 5:1 merges, concentrates, then uses recrystallizing methanol, obtains target compound.
(1) with embodiment 1 (1) part.
(2) with embodiment 1 (2) part.
(3) fermentation culture
Activated excellent aspergillus C2WU is made to concentration 10
9cfu/mL spore suspension, is inoculated in fermentation culture with 8% inoculum size, in 22 ℃ of static fermentations, cultivates 25 days.
Wherein, the formula of fermentation culture is: starch 3g, wheat bran 14g, yeast extract paste 6g, KH
2pO
40.5g, MgSO
47H
2o 0.4g, seawater 1000mL.
(4) cyclic peptide compounds preparation
After rod aspergillus C2WU fermentation culture, get 5L fermentation culture, centrifuging and taking supernatant obtains fermented liquid; After fermented liquid is concentrated, with 10g diatomite, mix sample, 1L ethyl acetate backflow, carries out purification on normal-phase silica gel column chromatography for separation (200-300 order, 1kg; Silicagel column size L50mm,
12mm), the petrol ether/ethyl acetate mixed solution with volume ratio 9:1,5:1,1:1,1:3,1:9 carries out gradient elution successively, each 300mL; TLC detects cut, and the cut of collecting wash-out ratio 5:1 merges; Reversed-phase silica gel column chromatography or high-efficient liquid phase chromatogram purification for target fraction, with methanol-water (60-40) wash-out, detect wavelength 254nm, and the cut of collecting 57min merges, concentrates, then uses recrystallizing methanol, obtains target compound.
Embodiment 3
(1) with embodiment 1 (1) part.
(2) with embodiment 1 (2) part.
(3) fermentation culture
Activated excellent aspergillus C2WU is made to concentration 10
7cfu/mL spore suspension, is inoculated in fermentation culture with 12% inoculum size, in 25 ℃ of static fermentations, cultivates 20 days.
Wherein, nutrient solution formula is: sucrose 20.0g, yeast extract 10.0g, malt extract 20g, MgSO
47H
2o 0.4g, KH
2pO
40.4g, seawater 1000mL.
(4) cyclic peptide compounds preparation
After rod aspergillus C2WU fermentation culture, fermentation culture is centrifugal, obtain respectively mycelium and fermented liquid.
Get mycelium and carry out vacuum-drying, dry weight obtains 253g, with methanol extraction (cold soaking) 3 times (3 * 1L), obtains methanol extract liquid, the concentrated medicinal extract 13g that obtains; 500mL distilled water suspendible for medicinal extract, obtains aqueous suspension; Aqueous suspension is extracted with ethyl acetate (3 * 3L) 3 times, is extracted liquid A; Fermented liquid (30L) is extracted with ethyl acetate (3 * 20L) 3 times, is extracted liquid B;
Extraction liquid A and extraction liquid B are merged, use purification on normal-phase silica gel column chromatography for separation, the petrol ether/ethyl acetate mixed solution with volume ratio 9:1,5:1,1:1,1:3,1:9 carries out gradient elution successively, each 300mL; TLC detects cut, collects the cut that wash-out ratio is 1:3, with preparation HPLC, carries out purifying: flow velocity 8mL/min, detects wavelength 254nm, with methanol-water (15-85) wash-out; Collect 28min cut, utilize Sephadex LH-20column to carry out purifying, then through preparation HPLC purifying, flow velocity 8mL/min, detects wavelength 254nm, with methanol-water (15-85) wash-out, collects 28min cut, obtains target compound.
Adopt HPLC to carry out Purity to the target compound making, purity is greater than 95% sample and uses mass spectrum and nuclear magnetic resonance technique to carry out Structural Identification, and nucleus magnetic resonance is measured with Bruker AVANCE DRX-500NMR Sectrometer, mark in TMS does; High resolution mass spectrum is measured with Agilent6210TOF LC/MS; Bruker Esquire 3000 for electrospray ionization mass spectrum ESI-MS
plusspectrometer measures, infrared use NicoletAvatar-360FT-IR infrared spectrometer.
The one-dimensional NMR analytical results of target compound is in Table 1, and two-dimentional NMR analytical results is shown in Fig. 1, and circular dichroism spectrum analytical results is shown in Fig. 2, and nuclear magnetic spectrum is shown in Fig. 3-8, and infared spectrum is shown in Fig. 9.
NMR data (the CDCl of table 1 cyclic peptide compounds
3)
| Position | δ C | δ H(J?in?Hz) |
| D-phenyllactic?acid | ? | ? |
| 1 | 169.8,C | ? |
| 2 | 71.5,CH | 5.51t(7.5) |
| 3 | 37.2,CH 2 | 3.39,dd(13.6,7.5);3.25,(13.6,7.5) |
| 4 | 135.5,C | ? |
| 5/9 | 129.6,CH | 7.31, |
| 6/8 | 128.7,CH | 7.34,overlap |
| 7 | 127.4,CH | 7.31,overlap |
| anthranilic?acid?I | ? | ? |
| 10 | 167.5,C d | ? |
| 11 | 127.4 | ? |
| 12 | 129.6,CH | 7.62,d(7.8) |
| 13 | 126.5,CH | 7.30,overlap |
| 14 | 132.7,CH | 7.44,t(7.8) |
| 15 | 126.1,CH | 7.19,d(7.8) |
| 16 | 134.8,C | ? |
| NH | ? | 8.58,s |
| anthranilic?acid?II | ? | ? |
| 17 | 167.4,C | ? |
| 18 | 123.1,C | ? |
| 19 | 126.5,CH | 7.56,d(7.8) |
| 20 | 123.2,CH | 7.03,t(7.8) |
| 21 | 132.2,CH | 7.40,t(7.8) |
| 22 | 121.9,CH | 8.48,d(7.8) |
| 23 | 137.9,C | ? |
[0077]?
| NH | ? | 10.17,s |
| glycine | ? | ? |
| 24 | 167.5,C | ? |
| 25 | 54.1,CH 2 | 5.25,d(14.8);3.10d(14.8) |
| 26 | 35.9,CH 3 | 3.01,s |
Through high resolution mass spectrum and electrospray ionization mass spectrum, measure, the molecular weight of target compound is 458.1716, the analytical results of associative list 1, Fig. 1-9, and known this material is cyclic peptide compounds, molecular formula is C
26h
24n
3o
5, structural formula is shown below, and called after clavatustide B determines that 2 absolute configurations are R type:
The anti-tumor activity analysis of embodiment 5 cyclic peptide compounds
HepG2 cell cultures is in containing the RP-MI1640 substratum of 10% calf serum, penicillin 100IU/mL and Streptomycin sulphate 100g/mL, and every 3d changes liquid 1 time, and every 5d goes down to posterity 1 time.Cell is all placed in 37 ℃.
The HepG2 cell in vegetative period of taking the logarithm, after fully digesting containing 0.25% tryptic PBS liquid, is diluted to 5 * 10 with RPMI1640 substratum
4the single cell suspension of/mL, is inoculated in 96 porocyte culture plates, each concentration multiple cropping 3 hole, every hole 180 μ L; Put dosing after 37 ℃ of incubator incubation 12h, the test liquid of the every Kong Jiahan different concns of medicine group (0.5 μ g/100 μ L, 1 μ g/100 μ L, 2 μ g/100 μ L, 3 μ g/100 μ L, 3.5 μ g/100 μ L, 4 μ g/100 μ L, 5 μ g/100 μ L) clavatustide B, the parallel blank group of establishing, cultivates 48h altogether.
By formula, calculate compound clavatustide B to the inhibiting rate of growth of tumour cell and half-inhibition concentration (IC
50).From experimental result, the IC of this compound to HepG2 cell
50=15 μ g/mL, show that this compound has good antitumor action.
The mechanism that suppresses HepG2 cell for understanding clavatustide B, HepG2 cell is fixing at 4 ℃ with 70% cold ethanol, cell and 0.5mL DNA Prep LPR(Coulter DNA-Prep Reagents kit after fixing, Beckman Coulter, USA) in dark condition, mix 20 minutes, then with flow cytometer, analyze, and with each phase cell mass of ModFit LT computed in software, calculation result is in Table 2.
Table 2 cell mass in each forms in period
| ? | G1?phase | S?phase | G2?phase |
| Clavatustide?B | 67.57% | 11.92% | 20.52% |
| Blank?control | 41.03% | 19.49% | 39.48% |
From table 2, Clavatustide B blocked by the induction HepG2 cell G1 phase, and suppressed G1/S conversion, thereby realized the growth-inhibiting to HepG2 cell.
Get 0.5g cyclic peptide compounds Clavatustide B and mix with 10.5g PEG-4000, heating and melting, moves to after material in dripping pill drip irrigation, and liquid drops in 6～8 ℃ of whiterusss, and oil removing makes 300 of dripping pills.
Embodiment 7 is containing the preparation of cyclic peptide compounds lyophilized injectable powder
Get cyclic peptide compounds Clavatustide B 0.5g, glucose 4.5g, Sulfothiorine 0.9g and distilled water 1000mL, after said components mixes, lyophilize, 400 of packing, obtain.
Claims (8)
1. a cyclic peptide compounds clavatustide B, is characterized in that, structural formula is as shown in formula I:
2. the preparation method of cyclic peptide compounds clavatustide B as claimed in claim 1, is characterized in that, comprises the following steps:
(1) activated excellent aspergillus (Aspergillus clavatus) CCTCC No.M 2013421 is inoculated in fermentation culture, in 20-30 ℃ of fermentation culture 10-60 days;
(2), after having fermented, separation obtains mycelium and fermented liquid;
Mycelium is placed in to organic solvent lixiviate, obtains vat liquor, then with distilled water to vat liquor suspendible, obtain aqueous suspension, then with ethyl acetate or chloroform, aqueous suspension is extracted, be extracted liquid A, extraction liquid A obtains mycelium extract after concentrated;
Or, with ethyl acetate or chloroform, fermented liquid is extracted, be extracted liquid B, extraction liquid B obtains fermentation broth extract after concentrated;
(3) mycelium extract or fermentation broth extract are carried out to chromatographic separation, purification process, make cyclic peptide compounds clavatustide B claimed in claim 1.
3. preparation method as claimed in claim 2, is characterized in that, in step (1), the temperature of described fermentation culture is 20-30 ℃, and the time is 10-60 days.
4. preparation method as claimed in claim 3, is characterized in that, in step (1), the temperature of described fermentation culture is 22-26 ℃, and the time is 15-25 days.
5. preparation method as claimed in claim 2, is characterized in that, in step (2), described organic solvent is one or both in methyl alcohol, ethanol, ethyl acetate and acetone.
6. preparation method as claimed in claim 2, is characterized in that, in step (3), described chromatographic separation is purification on normal-phase silica gel column chromatography for separation, and eluent is petrol ether/ethyl acetate mixed solution.
7. the application of cyclic peptide compounds clavatustide B in preparing antitumor drug or tumor prevention protective foods as claimed in claim 1.
8. application as claimed in claim 7, is characterized in that, described antitumor drug is medicines resistant to liver cancer, and described tumor prevention protective foods is prevention of hcc protective foods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310574939.4A CN103641791B (en) | 2013-11-15 | 2013-11-15 | Cyclopeptide compound clavatustide B, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310574939.4A CN103641791B (en) | 2013-11-15 | 2013-11-15 | Cyclopeptide compound clavatustide B, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103641791A true CN103641791A (en) | 2014-03-19 |
| CN103641791B CN103641791B (en) | 2015-04-29 |
Family
ID=50247117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310574939.4A Expired - Fee Related CN103641791B (en) | 2013-11-15 | 2013-11-15 | Cyclopeptide compound clavatustide B, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103641791B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104087514A (en) * | 2014-06-26 | 2014-10-08 | 华南理工大学 | Aspergillus clavatus for producing feruloyl esterase and application thereof |
| CN113030302A (en) * | 2021-02-25 | 2021-06-25 | 宜宾五粮液股份有限公司 | Method for separating and identifying cyclic peptide and cyclic peptide ethyl ester in vinasse |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1616484A (en) * | 2004-09-27 | 2005-05-18 | 沈阳药科大学 | Novel cyclopeptide anti-tumor, anti-virus antibiotic active compound |
| CN103304635A (en) * | 2013-06-05 | 2013-09-18 | 西安交通大学 | Application of cyclopeptide compound for preventing tumors and preparation method of compound |
-
2013
- 2013-11-15 CN CN201310574939.4A patent/CN103641791B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1616484A (en) * | 2004-09-27 | 2005-05-18 | 沈阳药科大学 | Novel cyclopeptide anti-tumor, anti-virus antibiotic active compound |
| CN103304635A (en) * | 2013-06-05 | 2013-09-18 | 西安交通大学 | Application of cyclopeptide compound for preventing tumors and preparation method of compound |
Non-Patent Citations (3)
| Title |
|---|
| FEI HE ET AL.: "Asperterrestide A, a Cytotoxic Cyclic Tetrapeptide from the Marine-Derived Fungus Aspergillus terreus SCSGAF0162", 《J. NAT. PROD.》 * |
| JINKAI ZHENG ET AL.: "Cyclic Tripeptides from the Halotolerant Fungus Aspergillus sclerotiorum PT06-1", 《J. NAT. PROD.》 * |
| 蒋志龙等: "生物活性环肽研究进展", 《中国药物化学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104087514A (en) * | 2014-06-26 | 2014-10-08 | 华南理工大学 | Aspergillus clavatus for producing feruloyl esterase and application thereof |
| CN113030302A (en) * | 2021-02-25 | 2021-06-25 | 宜宾五粮液股份有限公司 | Method for separating and identifying cyclic peptide and cyclic peptide ethyl ester in vinasse |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103641791B (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107298671A (en) | Come from the secalonic acid H of penicillium oxalicum and prepare the application of anti-human colon cancer drug | |
| CN107298672B (en) | Application of seclenic acid I derived from penicillium oxalicum in preparation of anti-human colon cancer drugs | |
| CN110452247B (en) | Heteroterpene compound and preparation method and application thereof | |
| CN107353274A (en) | Come from the secalonic acid I of penicillium oxalicum and prepare the application of anti-human oesophagus cancer drug | |
| CN103724290B (en) | Cyclopeptide compound clavatustide A as well as producing strain, preparation method and application thereof | |
| CN106010980B (en) | A kind of endogenetic fungus Brazil class shell roundlet spore bacterial strain and its application | |
| CN103172507B (en) | Ophiobollin sesterterpine compound as well as preparation method and application thereof | |
| CN103641791B (en) | Cyclopeptide compound clavatustide B, and preparation method and application thereof | |
| CN107298669B (en) | Selenolonic acid I from penicillium oxalicum and application of medicine for resisting human oral epidermoid carcinoma | |
| CN109106702A (en) | Derived from application of 4-4 ' the isomerization secalonic acid D in terms of colon cancer of penicillium oxalicum | |
| CN105061446B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting nasopharyngeal carcinoma | |
| CN103787953A (en) | Compound Aspochalasin V and preparation method and application thereof | |
| CN112300243B (en) | Cyclopeptide compound and preparation method and application thereof | |
| CN102584615A (en) | Alkaloid compound as well as preparation method and application thereof | |
| CN102746995B (en) | Preparation method for isochromophilone VIII and application of same in preparation of antineoplastic drugs | |
| CN101603011A (en) | The method and the special strain therefore thereof that prepare the two glucosides of epipodophyllotoxin | |
| CN111807946B (en) | Pratennsinon A compound and preparation and application thereof | |
| CN102093187A (en) | Polyketone compounds and application thereof | |
| CN109182142B (en) | Penicillium dermatum and application thereof | |
| CN108660169A (en) | A method of fermentation prepares spine spore bacteriums antibiotic | |
| CN102168020B (en) | Marine-source fungus and application thereof | |
| CN105112322A (en) | Grisic quinone A, grisic quinone B, and preparation method and medical application of grisic quinone A and grisic quinone B | |
| CN115894519B (en) | Tripeptide alkaloid compound and preparation method and application thereof | |
| CN104212852B (en) | A kind of phenol piperazine class antitumor antibiotics and preparation method thereof | |
| CN103570652A (en) | Epoxy benzoanthraquinone compound as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150429 Termination date: 20151115 |
|
| EXPY | Termination of patent right or utility model |